Actively Recruiting
Phase 2 Study of BGB-16673 Combined with Sonrotoclax for Untreated Chronic Lymphocytic Leukemia CLL
Led by M.D. Anderson Cancer Center · Updated on 2026-10-29
40
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a combination treatment using the drug BGB-16673, a Bruton Tyrosine Kinase degrader, and sonrotoclax, a BCL-2 inhibitor, in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma CLLSLL. This open-label, single-group phase II study aims to assess how well this time-limited therapy works by measuring disease response and survival outcomes. Participants will receive oral doses of BGB-16673 combined with sonrotoclax on an outpatient basis. For those with a high tumor burden at risk of tumor lysis syndrome, hospitalization is recommended during dose increases for close monitoring. The study focuses on evaluating therapeutic activity, safety, tolerability, and time to disease remission through these investigational drugs. During the study, participants will undergo regular clinical assessments including blood tests to monitor disease status and side effects. Researchers will track measurable residual disease levels, overall response rates, progression-free and overall survival. Safety is monitored throughout, with adverse events recorded over approximately one year. The trial lasts until July 2033, with primary completion expected by July 2031.
CONDITIONS
Brief Title
A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Research Team
N
Nitin Jain, MBBS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here